📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-05 16:35
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
54 announcements match the current filters (relevance ≥ 5).
Anupam Rasayan Signs 6-Year Chemical Supply Contract with US Specialty Metal Major
Anupam Rasayan India Limited has entered into a 6-year long-term supply contract with a US-headquartered global specialty metal major. The contract covers the supply of a specialty chemical product to support the client's global operations. Commercial dispatches under the agreement are scheduled to begin from the latter half of Q3 FY27. Total consideration is volume-linked and not quantified in the filing.
Confidence: HIGH
What changedAnupam Rasayan signed a 6-year specialty chemical supply agreement with a US industrial major, diversifying beyond its traditional client base.
Why it mattersProvides multi-year revenue visibility and strengthens the company's international custom synthesis portfolio starting in FY27.
Contract duration: 6 yearsDispatch timeline: Latter half of Q3 FY27Order value: not disclosedTotal installed capacity: ~2,00,000+ MT
📅 Short termPositive for sentiment, though revenue contribution will only start in late FY27.
📈 Long termAdds multi-year order visibility and expands custom manufacturing into the global geological resource and specialty metals domain.
⚠ Risk flags
- Order value not quantified (volume-linked pricing)
- Execution lead time with dispatches starting only from Q3 FY27
Key Highlights
Signed a 6-year multi-year supply contract with a US-based specialty metal manufacturer
Commercial dispatches expected to commence from the second half of Q3 FY27
Marks entry and diversification into the geological resource sector segment
Aggregate manufacturing capacity across 8 facilities stands at ~2,00,000+ MT as of March 31, 2026
👀 What to Watch
Track management commentary in upcoming earnings calls regarding revenue potential and margin profile of this contract, as well as readiness for dispatches starting Q3 FY27.
CRISIL Keeps Anupam Rasayan's Rs 1,780 Cr Debt on Watch Developing on Bliss GVS Acquisition
CRISIL Ratings has maintained its 'CRISIL A+/Watch Developing' rating on Anupam Rasayan's Rs 1,620 crore bank facilities and Rs 160 crore non-convertible debentures. The rating watch reflects the pending acquisition of a 43.3% to 48.2% stake in Bliss GVS Pharma, targeted for completion in September 2026. CRISIL noted that ARIL will fund the acquisition through Rs 300 crore in fresh debt alongside non-voting equity from a global fund, limiting expected rating movement to at most one notch. Liquidity remains strong with FY27 projected cash accruals of Rs 280-350 crore against debt repayments of Rs 40 crore.
Confidence: HIGH
What changedCRISIL has continued its credit ratings on 'Rating Watch with Developing Implications' pending the final funding closure of ARIL's stake purchase in Bliss GVS Pharma.
Why it mattersConfirms the acquisition's debt footprint will be limited to ~Rs 300 crore (~11.8% of TTM revenue), containing leverage escalation and rating downgrade risks.
Total rated bank facilities: Rs 1620 CroreRated NCDs: Rs 160 CroreAcquisition debt addition: Rs 300 croreAcquisition debt vs TTM revenue: ~11.8%FY27 expected cash accrual: Rs 280-350 croreCash and equivalents (March 31, 2026): > Rs 378 crore
📅 Short termWatch resolution expected in September-October 2026 once the Bliss GVS transaction and funding approvals conclude.
📈 Long termIf successfully integrated alongside Jayhawk Fine Chemicals, the acquisition expands pharma formulation exposure and cushions agrochemical cyclicality.
⚠ Risk flags
- Integration and debt burden from the Bliss GVS Pharma acquisition
- High working capital intensity despite recent improvements in inventory days
Key Highlights
CRISIL reaffirmed 'CRISIL A+/Watch Developing' on Rs 1,620 Cr bank facilities and Rs 160 Cr NCDs.
Company to incur Rs 300 Cr debt to fund the Bliss GVS Pharma acquisition, with remainder from a global fund.
Acquisition of 43.3-48.2% stake in Bliss GVS Pharma is expected to close in September 2026.
Expected FY27 net cash accrual is Rs 280-350 Cr against debt repayment obligations of Rs 40 Cr.
Inventory days improved to 324 days as of March 31, 2026, down from 510 days a year prior.
👀 What to Watch
Track the formal completion and exact funding mix of the Bliss GVS Pharma transaction in September 2026 to see if CRISIL resolves the watch without a rating downgrade.
Anupam Rasayan Q1 FY27 Concall: 36% YoY Revenue Growth, USD 300M LOI with BASQUEVOLT
Anupam Rasayan released its Q1 FY27 earnings call transcript, highlighting a 36% YoY increase in consolidated total income. The company announced the global first commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry and signed an LOI with BASQUEVOLT representing a ~USD 300 million (~INR 2,500 Cr) opportunity over 10 years. Total cumulative signed LOIs and contracts now stand at ~INR 18,000 Cr (approx. 7.1x TTM revenue). Management also reiterated progress on the integration of Jayhawk Fine Chemicals and the pending acquisition of Bliss GVS Pharma.
Confidence: HIGH
What changedSubmission of the detailed transcript from the Q1 FY27 earnings conference call held on August 14, 2026.
Why it mattersProvides visibility into the execution of the INR 18,000 Cr contract pipeline, technological advances in flow chemistry, and margin synergies from global acquisitions.
Q1 FY27 YoY Income Growth: 36%BASQUEVOLT LOI Potential: ~USD 300 million (~INR 2,500 Cr)BASQUEVOLT LOI vs TTM Revenue: ~99% (over 10 years)Cumulative Signed LOIs and Contracts: INR 18,000 croresOrder pipeline vs TTM Revenue: ~7.1x
📅 Short termThe commentary confirms steady operational traction and new product launches (ETFA via flow chemistry), providing confidence in the ongoing FY27 performance.
📈 Long termIntegration of Jayhawk and Bliss GVS along with backward integration via Tanfac positions the company as a full-suite global CDMO/specialty chemicals platform.
⚠ Risk flags
- M&A execution and integration risks across overseas and domestic acquisitions
- Dependence on global automotive/EV demand for scale-up of new contracts
Key Highlights
Consolidated total income grew 36% YoY in Q1 FY27
Signed an LOI with BASQUEVOLT with a potential value of ~USD 300 million over 10 years
Cumulative signed contracts and LOIs reach ~INR 18,000 crores across long-term tenures
Pipeline includes 65+ pharma and polymer molecules in R&D and pilot stages
👀 What to Watch
Track the commercialization timeline of the BASQUEVOLT contract starting in FY27 and the closure/integration milestones of the Bliss GVS Pharma acquisition.
₹2,850 Cr LOI and 36% Revenue Growth in Q1 FY27 Investor Presentation
Anupam Rasayan reported a strong 36% YoY increase in consolidated revenue to ₹667.5 Cr for Q1 FY27, driven by new product commercialization. A major highlight is a new 10-year Letter of Intent (LOI) with BASQUEVOLT, S.A. valued at approximately $300 million (₹2,850 Cr), which exceeds the company's total TTM revenue. While EBITDA grew 35% to ₹174.9 Cr, PAT growth was limited to 6% (₹51.2 Cr) due to a 57% increase in depreciation and a 38% rise in finance costs. The company is also progressing with the ₹1,600 Cr acquisition of Bliss GVS Pharma to bolster its pharmaceutical CDMO platform.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results and announced a massive new long-term supply agreement alongside updates on its pharmaceutical acquisition strategy.
Why it mattersThe new ₹2,850 Cr LOI provides significant long-term revenue visibility, while the shift toward pharmaceutical and polymer CDMO (now 125+ products) aims to improve margins and reduce cyclicality.
Q1 FY27 Consolidated Revenue: ₹667.5 CrNew LOI Value: ₹2,850 CrLOI vs TTM Revenue: 112.4%Total Order Book: ₹17,496 CrBliss GVS Acquisition Cost: ₹1,600 CrConsolidated EBITDA Margin: 26%
📅 Short termThe stock may react positively to the strong top-line growth and the substantial new order win, though high interest costs remain a drag on the bottom line.
📈 Long termThe company is structurally pivoting toward high-value fluorination and pharma CDMO, supported by a massive order book that is nearly 7x its TTM revenue.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (₹49.2 Cr in Q1)
- Execution risk of the ₹17,496 Cr order book
- Integration risk of the Bliss GVS Pharma acquisition
Key Highlights
Signed a 10-year LOI with BASQUEVOLT, S.A. worth approximately ₹2,850 Cr ($300 million) for specialty chemicals.
Consolidated revenue grew 36% YoY to ₹667.5 Cr, while Standalone revenue grew 4% to ₹334.9 Cr.
Total order book and LOIs reached a cumulative value of ₹17,496 Cr as of Q1 FY27.
Proposed acquisition of Bliss GVS Pharma for ~₹1,600 Cr is progressing to strengthen the pharma CDMO segment.
Became the first company globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
👀 What to Watch
Watch for the successful completion of the Bliss GVS Pharma acquisition and the commercialization timeline of the BASQUEVOLT LOI, which is expected to start contributing in FY27.
36% Revenue Growth in Q1 FY27; ~$300M LoI Signed with BASQUEVOLT
Anupam Rasayan reported a strong 36% YoY revenue growth to Rs 667.5 Cr for Q1 FY27, driven by momentum in its specialty chemicals and CDMO platform. While EBITDA grew 35% to Rs 174.9 Cr with healthy margins of 26.2%, PAT growth was relatively muted at 6% YoY (Rs 51.2 Cr). A major highlight is the signing of a ~$300M (approx. Rs 2,500 Cr) Letter of Intent with BASQUEVOLT for a 10-year supply, which is nearly equivalent to the company's total TTM revenue. Additionally, the company became the first globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
Confidence: HIGH
What changedAnupam Rasayan reported its Q1 FY27 financial results and announced a significant long-term supply agreement alongside a technological milestone in flow chemistry.
Why it mattersThe ~$300M LoI provides long-term revenue visibility and validates the company's strategy in performance materials, while the ETFA commercialization demonstrates high-end R&D capabilities in complex fluorination.
Q1 FY27 Revenue: Rs 667.5 CrYoY Revenue Growth: 36%LoI Value: ~$300 millionLoI vs TTM Revenue: ~98.6%EBITDA Margin: 26.2%PAT Growth: 6%
📅 Short termThe stock is likely to react positively to the strong top-line growth and the massive $300M LoI announcement, which offsets the slower PAT growth.
📈 Long termThe company is structurally positioning itself as a high-tech CDMO player through its fluorination platform and U.S. footprint, with the BASQUEVOLT deal providing a decade of revenue tailwinds.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Muted PAT growth compared to revenue
- Execution risk on the large 10-year LoI
- High debt levels (Rs 1,574 Cr) relative to quarterly earnings
Key Highlights
Total Revenue for Q1 FY27 increased 36% YoY to Rs 667.5 Cr from Rs 490.7 Cr
Signed a ~$300M (Rs 2,500 Cr) Letter of Intent with BASQUEVOLT for a 10-year supply period
EBITDA grew 35% YoY to Rs 174.9 Cr with a stable margin of 26.2%
Commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry, a global first for this product
Total installed capacity reached 200,000+ MT across 8 manufacturing facilities as of March 2026
👀 What to Watch
Monitor the conversion of the BASQUEVOLT LoI into a definitive contract and the execution timeline for the Bliss GVS Pharma acquisition. Investors should also track if the high-value ETFA product helps improve net margins, which lagged revenue growth this quarter.
Anupam Rasayan Appoints Ravi Desai as COO to Oversee ₹8,919 Cr Order Book
Anupam Rasayan has promoted Mr. Ravi Desai to the position of Chief Operating Officer (COO) effective August 14, 2026. Mr. Desai, who previously served as the Sales Head, has been with the company since 2012 and possesses over 20 years of experience in the specialty chemicals industry. This internal appointment is strategic as the company scales operations to execute its significant ₹8,919 Cr order book and integrates the $150 million Jayhawk acquisition. His role will focus on aligning sales, manufacturing, and R&D to enhance operational efficiency.
Confidence: HIGH
What changedInternal promotion of the existing Sales Head, Mr. Ravi Desai, to the role of Chief Operating Officer.
Why it mattersEnsures leadership continuity and integrates sales strategy with plant operations during a high-growth phase where revenue reached ₹2,366 Cr in FY26.
Order Book: ₹8,919 CrIndustry Experience: 20+ yearsCompany Tenure: 14 yearsTTM Revenue: ₹2,366 Cr
📅 Short termNeutral; the market typically views internal promotions as a sign of stability rather than a catalyst for immediate price movement.
📈 Long termPositive for operational execution as the new COO has deep institutional knowledge across both sales and manufacturing functions.
Key Highlights
Appointment of Mr. Ravi Desai as COO effective August 14, 2026
Mr. Desai brings over 20 years of extensive experience in specialty chemicals
Internal promotion of the existing Sales Head who has been with the firm since 2012
Company is currently managing a massive order book of ₹8,919 Cr
The appointee will continue as a Key Managerial Personnel (KMP) of the company
👀 What to Watch
Monitor if this leadership transition leads to improved execution of the ₹8,919 Cr order book and stabilization of operating margins, which stood at 22.2% in FY26.
₹32.0 Cr Standalone PAT in Q1 FY27; Ravi Desai Appointed as COO
Anupam Rasayan reported standalone revenue of ₹328.8 cr for Q1 FY27, a 4.2% increase YoY from ₹315.7 cr, but an 11.3% sequential decline from Q4 FY26. Standalone PAT stood at ₹32.0 cr, up 7.8% YoY from ₹29.7 cr, though it fell 24.5% from the previous quarter's ₹42.4 cr. Finance costs rose significantly to ₹42.1 cr from ₹33.7 cr in the year-ago period. The company also appointed Ravi Desai as Chief Operating Officer (COO) and confirmed the liquidation of its step-down subsidiary, Monitchem Kansas S.a.r.l.
Confidence: HIGH
What changedRelease of Q1 FY27 standalone financial results and the appointment of a new Chief Operating Officer.
Why it mattersThe results show stable year-on-year performance but highlight sequential pressure and a rising interest burden, which investors must weigh against the company's long-term fluorination growth strategy.
Standalone Revenue (Q1 FY27): ₹328.8 crStandalone PAT (Q1 FY27): ₹32.0 crFinance Costs (Q1 FY27): ₹42.1 crQ1 Revenue vs TTM Revenue: ~13.9%YoY Revenue Growth: 4.2%
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the sequential decline in revenue and profit despite the YoY growth.
📈 Long termStructural growth remains tied to the successful integration of the Jayhawk acquisition and the expansion of the high-value fluorination platform.
⚠ Risk flags
- Rising finance costs
- Sequential revenue decline
- Agrochemical sector demand pressure
Key Highlights
Standalone Revenue from Operations reached ₹328.8 cr in Q1 FY27 vs ₹315.7 cr in Q1 FY26.
Standalone Profit After Tax (PAT) reported at ₹32.0 cr for the quarter.
Finance costs increased by 24.9% YoY to ₹42.1 cr, impacting net margins.
Ravi Desai appointed as Chief Operating Officer effective August 14, 2026.
Step-down subsidiary Monitchem Kansas S.a.r.l liquidated effective June 30, 2026.
👀 What to Watch
Monitor the impact of the new COO on operational efficiency and the progress of the ₹8,919 cr order book execution amidst rising finance costs.
₹829 Cr Open Offer: Anupam Rasayan to acquire 26% stake in Bliss GVS Pharma
Anupam Rasayan has issued a formal Letter of Offer to acquire up to 2.77 crore shares (26% stake) of Bliss GVS Pharma Limited. The offer is priced at ₹299 per share, implying a total cash consideration of approximately ₹829 crore. This transaction is significant, representing roughly 35% of Anupam Rasayan's TTM revenue and 25.6% of its net worth. The acquisition is being made alongside Mates Visa Consultancy as a Person Acting in Concert (PAC).
Confidence: HIGH
What changedAnupam Rasayan has progressed from the initial announcement to the formal 'Letter of Offer' stage for a significant minority stake in Bliss GVS Pharma.
Why it mattersThis represents a major strategic expansion into the pharmaceutical sector, utilizing a substantial portion of the company's balance sheet (approx. 25% of net worth) to diversify its life sciences portfolio.
Offer Price per Share: ₹299.00Maximum Shares to Acquire: 2,77,26,848Stake Percentage: 26.00%Estimated Deal Value: ₹829.03 CrDeal Value vs TTM Revenue: ~35%Deal Value vs Net Worth: ~25.6%
📅 Short termThe stock may experience volatility as the market assesses the high cash outflow and the strategic fit of Bliss GVS Pharma within Anupam's existing chemical operations.
📈 Long termIf successfully integrated, this could provide Anupam Rasayan with deeper forward integration into the pharma value chain, though it increases the complexity of the business model.
⚠ Risk flags
- Significant cash outflow of ₹829 crore
- Potential increase in debt-to-equity ratio (currently 0.49)
- Integration risk of a pharmaceutical target into a specialty chemical business
Key Highlights
Open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited.
Offer price fixed at ₹299.00 per share, to be paid in cash.
Acquisition represents 26.00% of the expanded voting share capital of the target company.
Total potential deal value estimated at ₹829.03 crore based on the offer price and share count.
Anupam Rasayan's TTM revenue is ₹2,366 crore, making this acquisition a major capital allocation move.
👀 What to Watch
Monitor the tendering period dates and the final acceptance ratio to see if Anupam Rasayan successfully reaches the 26% threshold. Investors should also watch for management's guidance on how this acquisition will be funded given the existing debt of ₹1,574 crore.
$300 Million LOI signed with BASQUEVOLT for battery specialty chemicals
Anupam Rasayan has signed a non-binding Letter of Intent (LOI) with Spain-based BASQUEVOLT for the potential supply of specialty chemicals for solid-state lithium batteries. The deal is valued at $300 million (approx. ₹2,500 Cr) over a 10-year period, representing a significant entry into the EV battery materials space. On an annualized basis, the potential revenue of ~$30 million (₹250 Cr) would contribute roughly 10.5% to the company's TTM revenue of ₹2,366 Cr. However, investors should note the LOI is currently non-binding and contingent on successful product development and a definitive agreement.
Confidence: HIGH
What changedAnupam Rasayan has secured a preliminary long-term supply commitment in the EV battery chemical space, moving beyond its traditional agrochemical and pharma focus.
Why it mattersThis marks a strategic diversification into high-value electronic chemicals, which could potentially offer higher margins and a more stable long-term revenue stream compared to cyclical agrochemicals.
Potential Order Value: $300 MillionContract Duration: 10 yearsAnnualized Value vs TTM Revenue: ~10.5%Total Value vs TTM Revenue: ~105%Existing Order Book: ₹8,919 Cr
📅 Short termThe stock may see positive sentiment due to the large headline value, though the non-binding nature of the LOI means immediate financial impact is nil.
📈 Long termIf commercialized, this provides a decade-long revenue visibility in a high-tech sector, supporting the company's 20-25% growth guidance.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Non-binding agreement
- Product development risk
- Long execution timeline
- Customer concentration in a niche technology (solid-state batteries)
Key Highlights
Potential cumulative revenue of $300 million over a 10-year supply period
Strategic partnership with BASQUEVOLT, S.A., a European developer of solid-state lithium batteries
Focuses on the high-growth electronic chemicals and EV battery domain
LOI is non-binding and subject to successful product development and definitive contract negotiation
Adds to an existing robust order book which stood at ₹8,919 Cr as per recent filings
👀 What to Watch
Monitor for the conversion of this non-binding LOI into a definitive supply agreement and updates on the product development timeline for the solid-state battery chemicals.
Anupam Rasayan First Globally to Commercialize ETFA via Flow Chemistry; $600M Market Potential
Anupam Rasayan has become the first company globally to commercialize Ethyl trifluoroacetate (ETFA) using a proprietary continuous flow chemistry platform. The product targets a significant global addressable market estimated at USD 500–600 million, serving the life sciences, pharmaceutical, and performance materials sectors. By utilizing flow chemistry instead of traditional batch processes, the company achieves better safety, scalability, and a lower environmental footprint. This launch strengthens the company's position in complex fluorination chemistry across domestic and international markets, including the USA and Japan.
Key Highlights
First company in the world to commercialize ETFA production using continuous flow chemistry technology.
Targets a global addressable market for ETFA estimated between USD 500 million and USD 600 million.
ETFA is a critical fluorinated building block used in high-value pharmaceutical and life science applications.
The flow chemistry platform offers superior operational efficiency and reproducibility compared to conventional batch processes.
Product launch covers both domestic and international markets, including major regions like the USA and Japan.
👀 What to Watch
Investors should view this as a significant technological milestone that could enhance margins and market share in the specialty chemicals space. Monitor the revenue contribution from ETFA in upcoming quarterly results to gauge the speed of commercial ramp-up.
Anupam Rasayan Files Open Offer for 26% Stake in Bliss GVS Pharma at ₹299 Per Share
Anupam Rasayan India Limited has filed a Draft Letter of Offer with SEBI for a mandatory open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited. The offer price is set at ₹299.00 per share, representing 26.00% of the target company's expanded voting share capital. The total potential cash consideration for this stake is approximately ₹829 crore. The tendering period is tentatively scheduled to open on July 16, 2026, and close on July 29, 2026.
Key Highlights
Mandatory open offer to acquire up to 2,77,26,848 shares (26% stake) of Bliss GVS Pharma Limited.
Offer price fixed at ₹299.00 per equity share, to be paid in cash.
Draft Letter of Offer filed with SEBI on June 8, 2026, by Manager to the Offer, SBI Capital Markets Limited.
Tentative schedule sets the offer opening date as July 16, 2026, and closing date as July 29, 2026.
The acquisition is triggered by an underlying Share Purchase Agreement (SPA) for substantial acquisition of shares and control.
👀 What to Watch
Investors should monitor the final SEBI observations on the Draft Letter of Offer and assess the strategic synergies of this acquisition for Anupam Rasayan against the significant capital outlay.
Anupam Rasayan Promoter Declares No Encumbrance on 31.80% Stake for FY26
Kiran Pallavi Investments LLC, a key promoter of Anupam Rasayan India Limited, has submitted its annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The promoter entity holds 3,62,06,896 equity shares, which constitutes 31.80% of the company's total equity capital. The filing confirms that no direct or indirect encumbrances or pledges were created on these shares during the reporting period. This disclosure provides assurance regarding the stability of the promoter's shareholding.
Key Highlights
Promoter Kiran Pallavi Investments LLC holds a significant 31.80% stake in the company.
Declaration confirms zero shares were pledged or encumbered during the financial year 2025-26.
The filing involves 3,62,06,896 equity shares held by the promoter entity.
Compliance submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 What to Watch
Investors can take comfort in the fact that a major portion of the promoter holding remains unencumbered, indicating no immediate debt-related stress at the promoter level. Maintain a watch on overall promoter holding trends in upcoming quarterly reports.
CRISIL Places Anupam Rasayan on 'Rating Watch' Following Bliss GVS Pharma Acquisition Plan
CRISIL has placed Anupam Rasayan's 'CRISIL A+' long-term and 'CRISIL A1' short-term ratings on 'Rating Watch with Developing Implications'. This action follows the company's plan to acquire a 43.3-48.2% stake in Bliss GVS Pharma, which involves a debt component of Rs 300 crore. While FY26 revenue grew to Rs 2,365 crore from Rs 1,439 crore, operating margins compressed to 22.19% from 27.67%. The company has shown significant improvement in its working capital cycle, with inventory days reducing from 510 to 324 days.
Key Highlights
CRISIL A+ rating assigned to new Rs 160 crore NCDs and placed on Watch Developing.
Total bank loan facilities enhanced to Rs 1,620 crore from Rs 1,369.82 crore.
FY26 revenue increased to Rs 2,365 crore, though margins fell to 22.19% due to limited cost pass-through.
Inventory days improved to 324 days (vs 510 days) and receivables to 148 days (vs 190 days).
Acquisition of Bliss GVS Pharma stake to be funded via Rs 300 crore debt and balance through equity.
👀 What to Watch
Investors should monitor the final funding mix of the Bliss GVS acquisition and its impact on the company's leverage. While the improvement in working capital is positive, the compression in operating margins warrants caution regarding cost management.
CRISIL Places Anupam Rasayan on 'Rating Watch' Following Bliss GVS Pharma Acquisition Plan
CRISIL Ratings has placed Anupam Rasayan India Limited's (ARIL) 'A+' rating on 'Rating Watch with Developing Implications' following the company's announcement to acquire a 43.3-48.2% stake in Bliss GVS Pharma. The acquisition is expected to be funded by ₹300 crore in debt and additional equity from a global investment fund. While FY26 revenue grew significantly to ₹2,365.46 crore, operating margins saw a compression to 22.19% from 27.67% in the previous year. The company's financial risk profile remains healthy with a net worth of ₹3,334 crore and improving working capital cycles.
Key Highlights
CRISIL placed ARIL's long-term (A+) and short-term (A1) ratings on 'Rating Watch with Developing Implications' due to the Bliss GVS Pharma acquisition.
Revenue for FY26 increased to ₹2,365.46 crore from ₹1,438.72 crore in FY25, driven by agrochemical and pharma segments.
Inventory days improved significantly, dropping to 324 days in FY26 from 510 days in FY25.
Total bank loan facilities rated were enhanced to ₹1,620 crore from ₹1,369.82 crore.
Liquidity remains strong with expected cash accruals of ₹280-350 crore against debt obligations of ₹40 crore in FY27.
👀 What to Watch
Investors should closely monitor the final funding mix and regulatory approvals for the Bliss GVS Pharma acquisition, as it will determine the long-term impact on leverage. While the business growth and working capital improvements are positive, the 'Rating Watch' indicates near-term uncertainty regarding the capital allocation strategy.
Anupam Rasayan FY26 Revenue Jumps 65% to ₹2,384 Cr; Announces Bliss GVS Pharma Acquisition
Anupam Rasayan delivered a landmark FY26 with consolidated revenue growing 65% Y-o-Y to ₹2,384 crores and PAT increasing to ₹222 crores. The company successfully diversified its revenue mix, reducing agrochemical dependence from 76% to 55% while scaling Pharma and Performance Materials. A significant strategic acquisition of Bliss GVS Pharma (43.3% to 48.2% stake) was announced to create an integrated pharmaceutical platform. Management reported strong operating cash flows of ₹334 crores and the completion of its major capex cycle, signaling a shift toward higher asset utilization.
Key Highlights
FY26 consolidated revenue reached ₹2,384 crores, up 65% Y-o-Y, with an EBITDA margin of 23%.
Pharma segment revenue grew 15-fold from ₹21 crores in FY22 to ₹339 crores in FY26.
Announced acquisition of 43.3% to 48.2% stake in Bliss GVS Pharma to expand into formulations and CDMO.
Operating cash flow improved significantly to ₹334 crores due to better working capital management.
Jayhawk Fine Chemicals acquisition completed with pro forma annual revenue of approximately $76 million.
👀 What to Watch
Investors should view the aggressive diversification into Pharma and the completion of the capex cycle as long-term value drivers. Monitor the integration of Bliss GVS and Jayhawk for synergy benefits and margin expansion in FY27.
Anupam Rasayan Allots ₹160 Crore NCDs to Aditya Birla Capital at 10.25% Interest
Anupam Rasayan India Limited has successfully allotted 16,000 secured, unlisted Non-Convertible Debentures (NCDs) worth ₹160 crore to Aditya Birla Capital. The debt carries a coupon rate of 10.25% p.a. and has a short tenure of 13 months, maturing in June 2027. A significant partial redemption of ₹99,500 per NCD is scheduled for September 2026, effectively making it a very short-term bridge loan. The funds are intended for debt repayment, group investments, and general corporate purposes.
Key Highlights
Allotment of 16,000 NCDs with a face value of ₹1,00,000 each, totaling ₹160 crore.
Fixed coupon rate of 10.25% p.a. with interest and partial principal payable by September 2026.
Secured by a first-ranking pledge over 31,50,000 shares held by Promoter Mr. Anand Sureshbhai Desai.
Proceeds to be utilized for repayment of existing debt facilities and investment in group companies.
The instrument is unlisted and was issued on a private placement basis to Aditya Birla Capital Limited.
👀 What to Watch
Investors should monitor the company's interest coverage ratio given the 10.25% cost of debt and the increase in promoter share pledging. The structured early redemption suggests this is a temporary liquidity arrangement rather than long-term leverage.
Anupam Rasayan FY26 Revenue Jumps 65% to ₹23,836 Mn; Annual PAT Up 39%
Anupam Rasayan reported a landmark FY26 with consolidated revenue growing 65% YoY to ₹23,836 Mn, driven by the Jayhawk acquisition and new product launches. While annual PAT rose 39% to ₹2,222 Mn, Q4 performance saw a slight dip in margins with PAT falling 11% YoY to ₹560 Mn. The company achieved its highest-ever operating cash flow of ₹3,343 Mn and is expanding its pharma presence through a stake acquisition in Bliss GVS Pharma. The integration of Jayhawk and focus on high-value chemistries like Performance Materials remain key growth drivers.
Key Highlights
Consolidated FY26 revenue increased by 65% YoY to ₹23,836 Mn, while EBITDA grew 32% to ₹5,430 Mn.
Annual Profit After Tax (PAT) reached ₹2,222 Mn, representing a 39% growth compared to the previous financial year.
Successfully completed the acquisition of US-based Jayhawk Fine Chemicals and signed an agreement for Bliss GVS Pharma.
Achieved highest-ever operating cash flow of ₹3,343 Mn, reflecting improved operational efficiency and business scale.
Revenue mix diversified with Agrochemicals at 55%, Pharma at 20%, and Performance Materials at 18%.
👀 What to Watch
Investors should focus on the successful integration of Jayhawk and the upcoming Bliss GVS acquisition as they pivot the company toward higher-margin segments. While Q4 margins were slightly pressured, the strong annual cash flow and robust product pipeline support a long-term growth thesis in the CDMO space.
Anupam Rasayan FY26 Revenue Surges 65% to ₹23,836 Mn; Strategic Acquisitions Drive Growth
Anupam Rasayan reported a strong FY26 with consolidated revenue growing 65% YoY to ₹23,836 Mn and PAT increasing 39% to ₹2,222 Mn. The year was marked by the successful integration of Jayhawk Fine Chemicals and a new agreement to acquire a controlling stake in Bliss GVS Pharma. While annual performance was robust, Q4FY26 saw a margin contraction with EBITDA declining 6% YoY despite revenue growth. The company achieved its highest-ever operating cash flow of ₹3,343 Mn, supported by new product launches and expanded MNC partnerships.
Key Highlights
Consolidated FY26 revenue reached ₹23,836 Mn, a 65% YoY increase, driven by new products and acquisitions.
Full-year PAT grew 39% YoY to ₹2,222 Mn, though Q4 PAT declined 11% to ₹560 Mn due to margin pressure.
Completed the acquisition of US-based Jayhawk Fine Chemicals and signed a deal for Bliss GVS Pharma.
Generated record operating cash flow of ₹3,343 Mn, reflecting improved operational efficiency.
Diversified revenue mix with Agrochemicals at 55% and Performance Materials growing to 18%.
👀 What to Watch
Investors should monitor the successful integration of recent acquisitions and the recovery of margins which dipped in Q4. The shift towards high-value performance materials and pharma provides a long-term growth runway.
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma; Open Offer Announced
Anupam Rasayan India Limited has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Limited, alongside an open offer to public shareholders. The acquisition is being financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments. This strategic move aims to create an integrated life sciences platform, combining Anupam's specialty chemical expertise with Bliss GVS's finished dosage formulation capabilities. Bliss GVS brings a portfolio of over 150 branded formulations and US FDA/EU-GMP approved manufacturing facilities.
Key Highlights
Acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma plus a mandatory Open Offer
Financing structured via Rs 300 crore term loan and non-voting equity instruments
Bliss GVS is a global leader in suppositories and pessaries with 150+ branded formulations
Strategic vertical integration from Key Starting Materials (KSMs) to finished dosage forms
Access to US FDA, WHO-GMP, and EU-GMP certified manufacturing facilities in Maharashtra and Daman
👀 What to Watch
This is a major strategic expansion for Anupam Rasayan into the pharmaceutical formulation space; investors should monitor the acquisition valuation and the progress of the open offer. The integration is expected to unlock synergies in regulated markets like Europe and the US.
Anupam Rasayan to Acquire 43.3%-48.2% Stake in Bliss GVS Pharma
Anupam Rasayan (ANURAS) has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma, along with a mandatory Open Offer to public shareholders. The acquisition is being financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments for the balance. This strategic move allows ANURAS to vertically integrate its business from custom synthesis (KSMs) to finished dosage formulations. Bliss GVS brings a diversified portfolio of over 150 branded formulations and a strong international presence across Africa, Asia, and Latin America.
Key Highlights
Acquisition of 43.3% to 48.2% equity stake in Bliss GVS Pharma plus an Open Offer.
Financing includes a Rs 300 crore term loan and non-controlling non-voting equity instruments.
Bliss GVS Pharma offers a portfolio of 150+ branded formulations with US FDA and EU-GMP certified facilities.
Strategic shift towards an integrated life sciences platform spanning KSMs to finished dosages.
👀 What to Watch
Investors should view this as a major strategic expansion that enhances the company's value chain and market reach. Monitor the final acquisition price and the impact of the Rs 300 crore debt on the company's leverage ratios.
